Phase 1 Trial of <i>Withania somnifera</i> Leaf Extract (RH324) in Advanced Non-Small Cell Lung Cancer Including [ <sup>18</sup> F]FDG PET/CT as a Short-Term Metabolic Biomarker to Assess Efficacy: A Novel Model for Assessment of Complimentary Therap
Authors
Herbert B. Newton (ORCID: https://orcid.org/0000-0003-2291-7568)
Phase 1 Trial of Withania somnifera Leaf Extract (RH324) in Advanced Non-Small Cell Lung Cancer Including [ 18 F]FDG PET/CT as a Short-Term Metabolic Biomarker to Assess Efficacy: A Novel Model for Assessment of Complimentary Therap
Herbert B. Newton, Arash Kardan, Raymond F. Muzic, Jin Uk Heo et al.
Journal
Integrative Cancer Therapies
Topics
Phytochemicals and Medicinal Plants
article
Phase 1 Trial of Withania somnifera Leaf Extract (RH324) in Advanced Non-Small Cell Lung Cancer Including [ 18 F]FDG PET/CT as a Short-Term Metabolic Biomarker to Assess Efficacy: A Novel Model for Assessment of Complimentary Therap
Herbert B. Newton, Arash Kardan, Raymond F. Muzic, Jin Uk Heo, Afshin Dowlati, Santosh Rao
article en
Abstract
No abstract available for this paper.
Publication Tag
Integrative Cancer TherapiesVol. 25
Institutions
Baylor College of Medicine (US), University Hospitals of Cleveland (US), University Hospitals Seidman Cancer Center (US)